Synchron has secured $200 million in Series D funding to advance its brain-computer interface technology, signaling strong investor confidence and promising growth in the neurotechnology sector.

Target Information

Synchron, a pioneering company in the brain-computer interface (BCI) sector, has successfully raised $200 million in its Series D funding round. Founded in 2017 and led by Thomas Oxley, Synchron aims to revolutionize how humans interact with technology by unlocking the brain's computational capabilities. Their flagship product, the Stentrode device, represents a significant advancement in BCIs, enabling users to interact with devices using their thoughts. Since its inception, Synchron has made substantial progress, including significant clinical milestones and funding, evidencing a strong belief in its technology and long-term vision.

Industry Overview in the United States

The brain-computer interface industry in the United States is experiencing rapid growth, spurred by advancements in neural technology and a surge in investment. As of 2025, over $1 billion has been invested in the implanted BCI sector alone, indicating a robust interest in neurotechnology's potential applications. This growth is driven by the promise of BCIs in various domains, including medical rehabilitation and augmenting human capabilities.

Currently, major players in the BCI market are diversifying their offerings, moving beyond basic motor control BCI systems to include capabilities such as speech restoration a